Subsequently, the results of the multi-center ELISA validation clearly demonstrated that the levels of anti-OLA1 autoantibody were significantly elevated in HCC patients at three clinical centers, and had higher sensitivity in ANHCC patients. This evidence concerns the gene OLA1 and hepatocellular carcinoma.